On May 16, 2022, Dr. Li Ming, CEO of ZSHK Laboratories Limited ("ZSHK"), visited Ms. Sabrina Chan, Senior Executive Director of The Hong Kong Association of the Pharmaceutical Industry (“HKAPI") in Hong Kong, China, to discuss what preclinical CROs can do for this city in biopharmaceutical research and development.
As a further discussion following the initial meeting in January, Dr. Li introduced the business focus and plans of the company, as a new member of HKAPI, to Ms. Chan. To begin with, Ms. Chan congratulated ZSHK for it joining the HKAPI family. She hoped that ZSHK's presence in Hong Kong could facilitate the development of biopharmaceutical industry in this city and accelerate new drug development.
Ms. Chan invited Dr. Li to speak in upcoming HKAPI conferences/forums on pharmaceutical R&D, preclinical and clinical studies, and other related topics. She also invited ZSHK to participate in other relevant events organized by HKAPI.
Ma Junyi, Director of Public Affairs of ZSHK, also participated in this visit.
Left: Li Ming Middle: Sabrina Chan Right: Ma Junyi
About HKAPI
Formed in 1968, The Hong Kong Association of the Pharmaceutical Industry (HKAPI) has 32 full members, including the world’s top 20 companies engaged in the research and development of pharmaceuticals. Our member companies provide over 70% of the prescription medicines in Hong Kong.
Updating members with important information in the local pharmaceutical market, the Association aims to improve the overall well-being of Hong Kong people by making recommendations on healthcare policies,
as well as the relationship among our member companies, the government and the community.
About ZSHK
ZSHK Laboratories Limited (“ZSHK”) is a biopharmaceutical pre-clinical research and development service company. Its main business is pre-clinical research and evaluation services for drugs and medical devices. A one-stop R&D service platform, it renders research services in pharmacology and pharmacodynamics, pharmacokinetics, safety evaluation and other services for pharmaceutical companies and R&D organizations worldwide. ZSHK has independent laboratories in Hong Kong Science and Technology Park, Pingshan District of Shenzhen, Guangdong Province, and Suzhou Industrial Park of Jiangsu Province. Actively deploying R&D supply chain construction, ZSHK has established breeding and scientific research bases in Hunan for experimental dogs and Guangxi for non-human primates.
Related link: http://www.hkapi.hk/zh/2022/01/17/welcoming-new-members/
